Core Viewpoint - The company primarily engages in the research, production, and sales of steroid drug raw materials, with a focus on progesterone products for gynecological and family planning medications [2] Group 1: Company Operations - The company is involved in the development, production, and sales of steroid drug raw materials [2] - The company's fundraising projects and steroid raw material production projects include the extension of progesterone products for downstream applications [2] - The company's products are categorized based on sales regions, which include domestic and international sales [2]

Group 1 - The company, Gongtong Pharmaceutical, announced a share buyback program, repurchasing approximately 970,000 shares, which represents 0.84% of its total share capital, with a total transaction amount of about 19.77 million yuan [1] - The highest transaction price during the buyback was 22.25 yuan per share, while the lowest was 13.15 yuan per share [1] - As of the report, Gongtong Pharmaceutical's market capitalization stands at 2.5 billion yuan [1] Group 2 - For the first half of 2025, the company's revenue composition shows that steroid drug raw material manufacturing accounts for 99.91%, while other businesses contribute only 0.09% [1]

Group 1 - The company, Gongtong Pharmaceutical, announced the convening of its third board meeting on August 5, 2025, to discuss asset acquisition and related transactions [2] - For the year 2024, Gongtong Pharmaceutical's revenue composition is entirely from the manufacturing of steroid drug raw materials, accounting for 100.0% [2]